Nano


Chronic inflammatory diseases – MS being the most common – are severely debilitating. Existing therapeutic protocols often mitigate symptoms, yet cannot cure such ailments. Nanotechnology offers a possible lifeline to sufferers, as French researchers explore the colossal potential of molecule-sized medicines.


Phosphorous- containing dendrimers:


a new treatment for MS


Medicine is hoping to make giant strides: within the smallest scales. Measured in nanometers, synthetic, molecule-sized remedies promise revolutionary new treatments for illnesses like cancer and Parkinson’s


disease. are Dendrimer-based


therapies are a fast evolving frontier of this technology. Defined as ‘tree like’ polymers, dendrimers


repetitively structured


molecules, with a typically symmetrical structure which ‘branches’ outward from their core. Two-dimensionally visualised on paper, many of the fifty plus variations


90


catalogued to date resemble elegant, geometric patterns; snowflakes encircled by casing. This aesthetic grace is no accident of design, however. First synthesised in 1978, dendrimers possess a number of malleable properties which enhance their agency as nanotools, a role in which their construction becomes integral. Shape, size and weight of a dendrimer’s


form can be precisely modified – key to satisfying rigorous healthcare criteria, and characteristics which render them attractive vehicles for a number of bio-medical


techniques. Because of their minute


dimensions and globular shape, dendrimers are expert carriers of biomolecules and biomimics – technologies which craftily enter the human physique, and emulate the behaviour and characteristics of naturally occurring molecules to interact with cells. Located on the outermost periphery of the molecule’s shell are active groups,’ which


can intricate nanodevices. Insight Publishers | Projects be combine with other customised agents


‘functional by


designers. These may work independently, or


to form


Page 1  |  Page 2  |  Page 3  |  Page 4  |  Page 5  |  Page 6  |  Page 7  |  Page 8  |  Page 9  |  Page 10  |  Page 11  |  Page 12  |  Page 13  |  Page 14  |  Page 15  |  Page 16  |  Page 17  |  Page 18  |  Page 19  |  Page 20  |  Page 21  |  Page 22  |  Page 23  |  Page 24  |  Page 25  |  Page 26  |  Page 27  |  Page 28  |  Page 29  |  Page 30  |  Page 31  |  Page 32  |  Page 33  |  Page 34  |  Page 35  |  Page 36  |  Page 37  |  Page 38  |  Page 39  |  Page 40  |  Page 41  |  Page 42  |  Page 43  |  Page 44  |  Page 45  |  Page 46  |  Page 47  |  Page 48  |  Page 49  |  Page 50  |  Page 51  |  Page 52  |  Page 53  |  Page 54  |  Page 55  |  Page 56  |  Page 57  |  Page 58  |  Page 59  |  Page 60  |  Page 61  |  Page 62  |  Page 63  |  Page 64  |  Page 65  |  Page 66  |  Page 67  |  Page 68  |  Page 69  |  Page 70  |  Page 71  |  Page 72  |  Page 73  |  Page 74  |  Page 75  |  Page 76  |  Page 77  |  Page 78  |  Page 79  |  Page 80  |  Page 81  |  Page 82  |  Page 83  |  Page 84  |  Page 85  |  Page 86  |  Page 87  |  Page 88  |  Page 89  |  Page 90  |  Page 91  |  Page 92  |  Page 93  |  Page 94  |  Page 95  |  Page 96  |  Page 97  |  Page 98  |  Page 99  |  Page 100  |  Page 101  |  Page 102  |  Page 103  |  Page 104  |  Page 105  |  Page 106  |  Page 107  |  Page 108  |  Page 109  |  Page 110  |  Page 111  |  Page 112  |  Page 113  |  Page 114  |  Page 115  |  Page 116  |  Page 117  |  Page 118  |  Page 119  |  Page 120  |  Page 121  |  Page 122  |  Page 123  |  Page 124  |  Page 125  |  Page 126  |  Page 127  |  Page 128  |  Page 129  |  Page 130  |  Page 131  |  Page 132